FORA Capital’s Heron Therapeutics HRTX Stock Holding History

FORA Capital’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,752	Closed	-$28K	–	993
2021 Q1	$28K	Sell	1,752 -13,049	-88%	-$233K	0.01%	643
2020 Q4	$313K	Buy	+14,801	New	+$257K	0.05%	397
2020 Q1	–	Sell	-17,562	Closed	-$413K	–	1161
2019 Q4	$413K	Buy	+17,562	New	+$389K	0.04%	442

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FORA Capital's HRTX Position: Q2 2021 in Review

FORA Capital sold out of Heron Therapeutics (HRTX) in Q2 2021, closing a stake of 1,752 shares — an estimated $28K sold.

FORA Capital first reported a position in HRTX in Q4 2019 and held it in 3 quarters. The position peaked at $413K in Q4 2019. 189 funds tracked by Wall St. Rank hold HRTX as of Q2 2021.

FORA Capital reported no remaining Heron Therapeutics position as of Q2 2021 after selling out during the quarter.
FORA Capital sold 1,752 Heron Therapeutics shares in Q2 2021, an estimated $28K.
FORA Capital first reported a position in Heron Therapeutics in Q4 2019 and held it in 3 quarters.
FORA Capital's Heron Therapeutics position peaked at $413K in Q4 2019.
189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.